The deoxynucleotide, dATP, is elevated 50-to 1,000-fold above normal in erythrocytes, lymphocytes, and bone marrow from a child with adenosine deaminase deficiency and severe combined immunodeficiency disease. The child, when 17 mo of age, was also excreting approximately 30 mg of deoxyadenosine per day in urine (normal is less than 0.1 mg/day). Urinary excretion of uric acid was decreased. Elevated dATP levels in lymphocytes and bone marrow, and increased urinary excretion of deoxyadenosine, persisted despite hypertransfusion of the child with irradiated erythrocytes from a donor with normal adenosine deaminase. Overproduction of deoxynucleotides by increased salvage of adenosine appears to be the primary metabolic abnormality in patients with adenosine de aminase deficiency.
INTRODUCTION
A deficiency of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) activity is associated with the clinical syndrome of severe combined immunodeficiency with impairment of both cellular and humoral immunity (1) . The nature of the metabolic abnormalities resulting from the enzyme defect and the causes of the selective effects on lymphoid cells are under investigation. Deoxyadenosine 5'-triphosphate and deoxyadenosine 5'-diphosphate are the most abundant nucleotides in erythrocytes from children with adenosine deaminase (ADA)' deficiency, in striking contrast to normal erythrocytes where deoxynucleotides are not detectable (2) (3) (4) . We wish to report Received for publication 21 June 1978 and in revised form 12 July 1978. Abbreviation used in this paper: ADA, adenosine de- Assay of deoxynucleotides. Deoxynucleotides were estimated using DNA polymerase (8) . Standard curves were prepared over the range of 0.2-1.0 nmol of the appropriate deoxynucleotide. The reactions were carried out for 45 min to assure total nucleotide incorporation into DNA. A 25-,ul aliquot of the reaction mixture was then spotted on glass fiber disks and processed (9) .
High performance liquid chromatography. Analyses of nucleoside pools from urine were carried out using a Varian model 8530 high pressure liquid chromatograph (Varian Associates, Palo Alto, Calif.) with a UV detector set at 254 nm. For nucleoside resolution, a strong cation-exchange column (2 mm x 25 cm) packed with Aminex A-7 resin (Bio-Rad Laboratories, Richmond, Calif.) was utilized at 52°C under isocratic conditions. The buffer consisted of 0.2 M ammonium formate, pH 4.55, with a flow rate of 5 ml/h and a pressure maximum of 2,000 psi (10).
RESULTS
We have reported greatly increased levels of adenine deoxynucleotides in the erythrocytes of this child with ADA deficiency and severe combined immunodeficiency (2, 3). Because of the child's young age and lymphopenia we were unable to obtain sufficient number of lymphocytes to measure nucleotide pool sizes. The child is now older and his immune status has improved somewhat, perhaps because of repetitive transfusion with irradiated erythrocytes over the past year and a half. Specimens of lymphocytes obtained from peripheral blood when the child was 17 and 21 mo of age have both shown tremendous elevations of the intracellular concentration of dATP (Table I) Samples of urine from our patient were examined for nucleosides by high performance liquid chromatography after chromatography on an anion-exchange column to remove nucleotides and free bases. Excretion of deoxyadenosine is normally so low (<0.1 mg/ day) that it cannot be detected. Large quantities of deoxyadenosine were excreted in the urine of our patient (Table II) . Values of 27.6 and 31.1 mg deoxyadenosine excreted/24 h were obtained on two occasions, 4 mo apart. Excretion of adenosine may also be elevated in the patient, 1.5 mg/day as compared with 0.5 mg/day in a normal child (Table II) . Uric acid excretion by our patient was lower than expected (Table II) and the uric acid/creatinine ratio was lower in the patient than in normal adults or children. Plasma from our patient was examined for deoxyadenosine and adenosine and none was detected.
Identification of deoxyadenosine in the urine was proved in several ways. Fig. IA shows the chromatogram of the patient's urine compared to urine from a normal person (Fig. 1G) . Urine from the patient, but not from the normal control, contains material eluting in the same position as deoxyadenosine. The positions of several nucleosides are indicated in Fig. 1 . The pool of nucleosides obtained from the patient's urine was treated with purified ADA from calf intestine. The treated urine was then examined by high performance liquid chromatography (Fig. 1B) . The peak previously seen in the position where deoxyadenosine elutes ( 1A) disappears after treatment of urine with ADA (Fig. 1B) . Final confirmation of deoxyadenosine as the abnormal metabolite in urine was obtained by gas chromatography-mass spectrometry. Samples of the deoxyadenosine isolated from urine by high performance liquid chromatography were derivatized and examined as described previously for our laboratory (3). The molecular ions produced coincided with those formed from a derivatized standard of deoxyadenosine.
DISCUSSION
Severe impairment of thymus-derived and bone marrow-derived cell immunity has been well established as the usual consequence of hereditary deficiency of ADA (1, 12) . The specific nature of the metabolic defect resulting from a deficiency ofADA activity has been puzzling. The recent identification of dATP as the principal abnormal metabolite in erythrocytes from several patients identified one metabolic consequence of inadequate levels of ADA. We have now shown that lymphocytes and bone marrow from an affected child also contain large quantities of dATP. The lymphocytes were obtained after the child had been treated for over a year by hypertransfusions with irradiated erythrocytes from a donor with normal ADA. Activity ofADA was normal and dATP was absent from erythrocytes of the patient at the time the lymphocytes were obtained. This shows that frequent transfusion of normal erythrocytes does not constitute a form of enzyme replacement therapy that corrects the metabolic abnormality in lymphocytes. Our immunodeficient child is excreting large quantities of deoxyadenosine. Other investigators have reported that little or no deoxyadenosine is excreted by children with ADA deficiency (4, 7) . The reason for the discrepancy between our and their results is not known. ADA deficiency is clinically heterogeneous. The level of ADA activity in cells does not always correlate with the severity of immunodeficiency disease. Whether the severity of the metabolic defect, e.g. level of excretion of deoxyadenosine, correlates better with severity of disease is not yet known.
Since deoxyadenosine is excreted in measurable quantities and accumulated in cells, deficiency of ADA 
